Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

Pfizer Profit Falls 32% As Global Trial Of COVID-19 Vaccine Candidate Begins

The U.S. drugmaker said net income fell to $3.43 billion, or 61 cents per share, in the quarter, from $5.05 billion, or 91 cents per share, a year earlier.

Photo Credit :

1595934908_egxYDn_2020_07_28T105522Z_1_LYNXNPEG6R0Q7_RTROPTP_4_PFIZER_RESULTS.JPG

Pfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.

The U.S. drugmaker said net income fell to $3.43 billion, or 61 cents per share, in the quarter, from $5.05 billion, or 91 cents per share, a year earlier.

Sales fell to $11.80 billion from $13.26 billion.

Pfizer and German biotech BioNTech drugmaker said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.

(Reuters)


Tags assigned to this article:
pfizer COVID-19 BioNTech drugmaker Health Crisis